Impact of Biomarkers on Personalized Medicine.
暂无分享,去创建一个
[1] D. Gerhold,et al. Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies , 2010, Nature Biotechnology.
[2] M. Ziman,et al. Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[3] Armin Koch,et al. Personalized medicine using DNA biomarkers: a review , 2012, Human Genetics.
[4] G. Eknoyan,et al. A history of diabetes mellitus or how a disease of the kidneys evolved into a kidney disease. , 2005, Advances in chronic kidney disease.
[5] G. Calin,et al. miRNAs and long noncoding RNAs as biomarkers in human diseases , 2013, Expert review of molecular diagnostics.
[6] C. Levy,et al. Influence of renal insufficiency on levels of serum ribonuclease in patients with multiple myeloma. , 1977, Journal of the National Cancer Institute.
[7] René Bernards,et al. Taming the dragon: genomic biomarkers to individualize the treatment of cancer , 2011, Nature Medicine.
[8] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[9] Darren Plant,et al. Genetic and epigenetic predictors of responsiveness to treatment in RA , 2014, Nature Reviews Rheumatology.
[10] C. Pui,et al. Pharmacogenomics and Individualized Medicine: Translating Science Into Practice , 2012, Clinical pharmacology and therapeutics.
[11] K. Strimbu,et al. What are biomarkers? , 2010, Current opinion in HIV and AIDS.
[12] S. Hanash,et al. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer , 2011, Nature Reviews Clinical Oncology.
[13] Duncan Ayers,et al. Long Non-Coding RNAs: Novel Emergent Biomarkers for Cancer Diagnostics , 2013 .
[14] Olufunmilayo I. Olopade,et al. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.
[15] O. Nemirovskiy,et al. Design and validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide in human urine: application as a biomarker of osteoarthritis. , 2010, Methods in molecular biology.
[16] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[17] D. Hoon,et al. Epigenetic biomarkers in skin cancer. , 2014, Cancer letters.
[18] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[19] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[20] D. Chan,et al. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges , 2013, Clinical Proteomics.
[21] C. Milne,et al. Trial watch: Personalized medicines in late-stage development , 2014, Nature Reviews Drug Discovery.
[22] K. Pantel,et al. Real-time liquid biopsy in cancer patients: fact or fiction? , 2013, Cancer research.